Project Grant HT94252510220
Award Date
5/1/25
Completion Date
4/30/28
Dollars Obligated
$1.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
The Defense Health Agency has awarded a $968,400 Project Grant to Mayo Clinic to develop a personalized approach to treating drug-resistant ovarian cancer. The grant, which began on June 1, 2024, and will run through May 31, 2028, is funded under the Military Medical Research and Development program (CFDA 12.420). This program supports biomedical research to improve the health and care of military service members, veterans, and their families. Through this award, Mayo Clinic will leverage its...
The Defense Health Agency awarded Dana-Farber Cancer Institute a $1,046,135 project grant under the Military Medical Research and Development program to conduct research titled "Drugging the Undruggable: Programming Ovarian Cancer Cells as the Next-Generation Immunotherapy." The three-year award runs from May 15, 2023 to May 14, 2026. As the prime recipient, Dana-Farber will leverage its expertise in tumor biology, immunology and drug development to research new therapies for ovarian...
The U.S. Department of Defense's Defense Health Agency awarded a 3-year, $954,000 Project Grant to the Massachusetts Institute of Technology (MIT) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "TUMOR-TARGETED NANOCARRIERS FOR EFFECTIVE IMMUNOMODULATION OF OVARIAN CANCER," supports advanced biomedical research focused on developing innovative tumor-targeted nanocarriers for effective immunomodulation of ovarian cancer. This...
The Defense Health Agency awarded a $778,092 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (DFCI) for the purpose of "ADVANCING PRECLINICAL STUDIES OF DUAL-TARGETED FINE-TUNED IMMUNE-RESTORING (DFIR) CAR-T CELL THERAPY TO ACHIEVE CURES OF HIGH-GRADE SEROUS OVARIAN CANCER." The project aims to conduct preclinical studies on a novel dual-targeted CAR-T cell therapy approach to treat high-grade serous...
The Defense Health Agency awarded Rutgers, The State University of New Jersey a $942,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support targeted chemotherapeutic and immunotherapeutic research for drug-resistant ovarian cancer. The three-year award beginning April 1, 2023 will fund Rutgers Biomedical and Health Sciences' investigation into medical solutions for this treatment-resistant form of ovarian cancer through innovative research...
The University of Southern California will receive $413,750 through September 2025 under a Project Grant from the Defense Health Agency to develop next-generation chimeric antigen receptor T cells targeting folate receptor 1 for the treatment of ovarian cancer. Funded through the Military Medical Research and Development program (CFDA 12.420), this award will support the grantee's applied medical research efforts to investigate innovative solutions for battlefield health care and transform...
The Defense Health Agency awarded a $619,500 Project Grant to the Sloan-Kettering Institute for Cancer Research, a non-profit organization in New York, NY. The grant is funded through the Military Medical Research and Development (CFDA 12.420) program and will support research to investigate the immunogenicity and targeting of shared neoantigens in adenoid cystic cancer over a 3-year period from September 1, 2023 to August 31, 2026. The research aims to transform health care for Service...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded Scripps Research Institute, a nonprofit biomedical research organization, a $529,125 project grant to investigate microglia dysfunction in MEF2C deficiency autism spectrum disorder with the goal of discovering targeted therapies. This 3-year award, effective September 30, 2024, will fund research aimed at improving the health and care of military service members, veterans, and their families...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $276,721 to Florida State University to improve targeted ovarian cancer therapy using the novel Notch pathway inhibitor auranofin. The award period runs from July 1, 2024 to June 30, 2027. The funded research aims to advance the scientific understanding and development of innovative treatments for ovarian cancer, a critical medical challenge for military...